Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenues
Royalty and licensing revenue	$ 8,600,811	$ 20,493,679	$ 19,056,999	$ 30,368,530
Treatment investment revenue	0	0	0	643,956
Grant and contract revenue	505,265	147,071	644,195	1,837,673
Total revenue	9,106,076	20,640,750	19,701,194	32,850,159
Operating expenses
General and administrative	2,729,098	3,211,022	8,138,571	9,389,630
Research and development	2,783,452	1,843,207	4,762,749	7,043,857
Sales and marketing	914,349	140,690	3,737,793	140,690
Royalty expense	1,951,947	4,850,807	4,288,701	6,098,882
Total operating expenses	8,378,846	10,045,726	20,927,814	22,673,059
Income (loss) from operations	727,230	10,595,024	(1,226,620)	10,177,100
Other income (expense)
Interest income	3,922	112,388	92,015	356,657
Loss on foreign exchange	(6,178)	(24,313)	(2,269)	(65,310)
Total other income (expense)	(2,256)	88,075	89,746	291,347
Income (loss) before income taxes	724,974	10,683,099	(1,136,874)	10,468,447
Income tax (expense) benefit	0	0	(39,000)	56,805
Net income (loss)	724,974	10,683,099	(1,175,874)	10,525,252
Other comprehensive loss:
Foreign currency translation adjustment	196,076	0	(114,644)	0
Total other comprehensive gain (loss)	196,076	0	(114,644)	$ 0
Comprehensive income (loss)	$ 921,050	$ 10,683,099	$ (1,290,518)
Net income (loss) per share of common stock:
Basic (in dollars per share)	$ 0.17	$ 2.64	$ (0.28)	$ 2.64
Diluted (in dollars per share)	$ 0.15	$ 1.97	$ (0.28)	$ 1.98
Weighted average shares outstanding used to compute net income (loss) per share:
Basic (in shares)	4,258,105	4,048,635	4,247,045	3,985,112
Diluted (in shares)	4,847,211	5,422,345	4,247,045	5,310,157